India's PLI Scheme Hits New Milestones, But Jobs Growth Slows

The Indian government's Production Linked Incentive (PLI) scheme has reached new milestones in its goal to boost domestic manufacturing. As of June 30, 2026, the scheme has disbursed ₹36,754 crore to beneficiary companies.

This is a significant increase from the previous update in December 2025, when the cumulative disbursement was ₹21,534 crore.

The PLI scheme aims to attract investment and boost exports by offering incentives to companies that invest in specific sectors. So far, it has attracted a cumulative investment of ₹2.58 lakh crore, generating production/sales of ₹23.79 lakh crore and exports of ₹15.53 lakh crore.

Notably, the pharmaceuticals sector has seen significant growth under the PLI scheme, with cumulative sales of over ₹3.64 lakh crore. The sector has also achieved a major milestone by localizing 1,931 pharmaceutical products, including 191 bulk drugs that were manufactured in India for the first time.

The government is also easing visa restrictions for foreign technical staff under the e-Production Investment Business Visa (e-B4) scheme, which was introduced last November. This move is expected to benefit Indian companies looking to hire foreign professionals for production-related work.